WASHINGTON, D.C. (March 16, 2022) – The Pharmaceutical Research and Manufacturers of America released the following statement on the war in Ukraine:
“We are deeply saddened by the war taking place against the people of Ukraine. The biopharmaceutical research industry is united in our mission of providing vaccines and treatments to all patients who need them. Like the broader health care sector, biopharmaceutical companies serve a critical humanitarian role in sustaining access to medicines and clinical trials for patients wherever they are. PhRMA’s member companies are working in a variety of ways to support those affected by this humanitarian crisis, including by providing free essential medicines, making monetary donations to non-profits providing aid, monitoring for supply chain disruptions, and addressing the safety of employees and their families through financial assistance, transportation and other resources.
“We condemn the violence unfolding against the people of Ukraine and hope for its immediate end.”
To learn more about individual company efforts, please visit the website set up by our European sister association, the European Federation of Pharmaceutical Industries and Associations’ (EFPIA), found here.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Over the last decade, PhRMA member companies have more than doubled their annual investment in the search for new treatments and cures, including nearly $101 billion in 2022 alone.